AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories
AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology
SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that its AI Nose has made a significant breakthrough in factory automation with 79% accuracy in detecting 761 samples across 22 different volatile organic compounds (VOCs). This is a remarkable technological advancement in industrial manufacturing safety and smart manufacturing.
During its over ten years of development in medical applications, the AI Nose consistently delivered excellent performance in multiple uses cases and is now expanding into the industrial sector. The technology shows promising potential to be a crucial tool in smart manufacturing with its effective capabilities for monitoring and preventing harmful gas leaks, ensuring efficient factory operations with worker safety.
The latest AI Nose breakthrough detects 22 different VOCs, covering several critical industrial use-cases that include:
Manufacturing Process Contamination Control: AI Nose can promptly detect leaks of photoresists and other substances, reducing contamination risks in manufacturing processes and improving product yield;
Health and Safety Assurance: Chemical leaks pose significant health risks. AI Nose's real-time response can significantly mitigate these dangers;
Fire Prevention: AI Nose can detect overheating in manufacturing equipment cables, thus reducing fire risks caused by electrical failures; and
Integrating gas sensing technologies within factories is a necessity in the modern smart manufacturing: AI Nose can optimize gas sensing with real-time feedback for powerful assurance on factory safety.
In the near future, Ainos intends to integrate AI Nose into smart factory's robotics systems. Robots with AI Nose can intelligently sense their surroundings and perform more complex tasks. Conventional robots lack the sense of smell, which causes difficulties in detecting hazardous gases or changes in surroundings. AI Nose equips robots with a human-like sense of smell, enhancing their ability to collaborate with human workers. This improved robot performance helps ensure a safer work environment and benefits mankind.
Ainos' latest AI Nose technology is set to revolutionize industrial automation by bringing more safety measures as well as efficiency to factory operations while further solidifying Ainos' leadership in VOC sensing.
Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Our latest milestone validates our thesis that VOC sensing, powered by AI Nose, has vast opportunities. Looking ahead, I see further room for accuracy improvements as we train AI Nose with more data from our codevelopers and smart manufacturing facilities. I believe AI Nose has the potential for becoming the sensory ‘nose' of AI, capable of digitizing smell."
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA). The Company's clinical-stage product pipeline includes VELDONA human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform.
The name "Ainos" is a combination of "AI" and "Nose" to reflect the Company's commitment to empowering individuals to manage their health more effectively with next-generation AI-driven POCT solutions. To learn more, visit https://www.ainos.com.
Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Safe Harbor Statement
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance," "potential," "outlook," "forecast," "should," "will" or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products ; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the "Risk Factors" section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ("SEC"), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.
The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
Investor Relations Contact
Feifei Shen
Email: IR@ainos.com
SOURCE: Ainos, Inc.
View the original press release on accesswire.com
